1 May 2022
10 Years of CAR-T
For this feature, the Phacilitate team explores key milestones from the last decade of CAR-T research, development, commercialization and delivery.
Latest Content
Latest Podcast Episodes
People and ideas that inspire the advanced therapies industry
Content services
Your Content Marketing Agency for Advanced Therapies
From creation to distribution, Phacilitate is a full service content marketing agency
Our eBooks & Infographics
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.
May 2022 marks the month 17-year-old Emily Whitehead, the first pediatric patient in the world to receive CAR-T cell therapy, celebrates a momentous milestone: 10 years’ cancer free. All month Phacilitate will be joining to celebrate 10 years of CAR-T!
Welcome to Phacilitate’s first Women in Advanced Therapies eBook, commemorating International Women’s Day 2022.
A snapshot of the industry’s approach to commercialisation, presented as a handy infographic.
A collection of the outcomes from the roundtables and panels that took place at Advanced Therapies Connect 2020
This e-book examines 15 of the world’s leading immuno-oncology biotechnology companies, providing you with an at-a-glance view plus more detailed information on how their pipelines are developing.
2017 was a milestone year for the immuno-oncology industry. There was big headline news; Novartis’ Kymriah and Kite’s submission of their ZUMA-1 trial to European regulators, as well as numerous incremental wins.
The pace of innovation across cell and gene therapy biotechs is gaining speed and it can be challenging to keep track of scientific developments, new technologies and who might be looking for their next big partnership.
A guide to the non-dilutive funding applications that are open or opening soon from the US and Europe.
What are the key commercialisation challenges associated with bringing a cell and/or gene therapy to a commercial scale?
